ZNTL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zentalis Pharmaceuticals Inc (ZNTL) is not a good buy for a beginner investor with a long-term strategy at this time. The technical indicators show a lack of clear upward momentum, the options data reflects low trading sentiment, and the financial performance is weak with declining net income and EPS. Additionally, there are no positive news catalysts or recent congressional trading activity to suggest confidence in the stock. Given the investor's preference for long-term investments, it would be prudent to wait for stronger financial performance or clearer positive signals before considering an investment.
The MACD is negative and expanding downward (-0.0229), indicating bearish momentum. RSI is neutral at 42.193, and moving averages are converging, suggesting no clear trend. The stock is trading below the pivot level (2.377), with support levels at 2.186 and 2.068, and resistance levels at 2.568 and 2.686.
NULL. No news, no significant hedge fund or insider trading trends, and no recent congressional trading data.
Technical indicators suggest bearish momentum, and options data reflects low trading sentiment.
In Q3 2025, revenue remained at 0 with no growth. Net income dropped to -$26.69 million (-33.54% YoY), EPS declined to -$0.37 (-33.93% YoY), and gross margin fell to 0 (-100.00% YoY). The company shows no signs of financial improvement.
No data on analyst ratings or price target changes available.
